Clinical trials: Acute Cardiovascular Disease
Pulmonary Embolism
Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System
The purpose of this European Post Market Follow-up Plan is designed to evaluate the safety, efficacy, adverse events and any new information that may surface regarding the use of the AngioJet Ultra PE Thrombectomy Catheter System…
- Trial name
- PERFUSE (NCT01638468)
- Testing
- AngioJet Ultra PE Thrombectomy System
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 7 people
- Sponsor
- Boston Scientific Corporation
Acute Stroke
Early Feasibility Study of the Nervive VitalFlow Stimulation for Acute Ischemic Stroke Patients
This Early Feasibility Study (EFS) is a multi-center, open-label single-arm study in 10 acute ischemic stroke (AIS) patients treated with VitalFlow-IS stimulation within 6 hours of symptom onset.
- Trial name
- NCT04801225
- Testing
- Non-invasive electromagnetic stimulation for acute stroke treatment
- Where
- 2 sites in United States
- Sponsor
- Nervive, Inc.
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Acute Ischemic Stroke
Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)
A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke
- Trial name
- NCT06040476
- Testing
- hUCB
- Volunteers
- 39 people
- Sponsor
- StemCyte, Inc.
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
Acute Coronary Syndrome
OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study
To evaluate the pharmacokinetic parameters of sirolimus release from the Svelte DES.
- Trial name
- NCT03716102
- Testing
- PCI with implantation with DES
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Svelte Medical Systems, Inc.
Acute Ischemic Stroke
Prospective Registry for Assessment of Acute Ischemic Stroke Patients Treated With Neurothrombectomy Devices in India
PRAAN is a post-market registry designed to collect real-world data associated with the use of Medtronic market release neurothrombectomy devices in acute ischemic stroke (AIS) patients from India.
- Trial name
- PRAAN (NCT05005962)
- Testing
- Neurothrombectomy
- Where
- 14 sites in India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Acute Ischemic Stroke
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NTS-104 TRIS will be administered as a single intravenous dose to healthy subjects at doses of 0.8, 4, 8 and 16 mg/kg in 4 Cohorts.
- Trial name
- NCT05547438
- Testing
- NTS-104 TRIS
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NeuroTrauma Sciences, LLC
Stroke
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of…
- Trial name
- NCT05395338
- Testing
- rt-PA
- Where
- China
- Volunteers
- 12,551 people
- Sponsor
- Boehringer Ingelheim
Coronary Heart Disease
SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)
The overall objective of this integrated analysis is to evaluate the clinical safety and efficacy of long-term treatment with darapladib enteric coated tablets, 160mg, as compared to placebo when added to standard of care in…
- Trial name
- NCT01636271
- Testing
- darapladib
- Volunteers
- 28,855 people
- Sponsor
- GlaxoSmithKline
Heart Decompensation
Study of the Sudden Heart Failure Participant Population in the US
An observational study using data from a large US electronic health record database to find participants hospitalized with ADHF who do not have a concurring heart attack
- Trial name
- NCT03566264
- Testing
- Non-Interventional
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Myocardial Infarction
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute…
- Trial name
- NCT00168792
- Testing
- Tenecteplase, PCI
- Where
- 176 sites in United States, Austria and 16 more
- Volunteers
- 1,671 people
- Sponsor
- Boehringer Ingelheim
Congestive Heart Failure
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
The purpose of this study is to assess a dose titration scheme, of a new drug (BAY58-2667) given intravenously, to evaluate if this is safe and can help to improve the well-being, symptoms (e.g.
- Trial name
- NCT00559650
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 72 sites in United States, Canada and 15 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Acute Ischemic Stroke
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment.
- Trial name
- EAISE (NCT04309474)
- Testing
- Elezanumab
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 121 people
- Sponsor
- AbbVie
Stroke, Acute, Stroke, Ischemic
Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy
Stroke remains one of the main socially significant problems in the healthcare in the third millennium. The lethality in persons with history of stroke by the end of the 1st year of disease is high.
- Trial name
- NCT06514976
- Testing
- Cytoflavin
- Where
- 17 sites in Russia
- Volunteers
- 562 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Acute Ischemic Stroke
A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)
The SUMMIT MAX study is a prospective, randomized, controlled, interventional clinical trial to evaluate the safety and effectiveness of the Route 92 Medical MonoPoint® Reperfusion System with the Hi Point 88 and HiPoint 70…
- Trial name
- NCT05018650
- Testing
- Route 92 Medical Reperfusion System
- Where
- 30 sites in United States, New Zealand
- Volunteers
- 250 people
- Sponsor
- Route 92 Medical, Inc.
Acute Stroke
REcanalization of Distal Cerebral Vessels in Acute Stroke Using ApeRio®
The purpose of the REVISAR PMCF is to collect data in clinical practice of the APERIO® and APERIO® Hybrid(17) Thrombectomy Device, which are intended to restore blood flow in the neurovasculature by removing thrombus in patients…
- Trial name
- NCT04479020
- Testing
- Mechanical Thrombectomy
- Where
- 11 sites in Germany
- Volunteers
- 134 people
- Sponsor
- Acandis GmbH
Unstable Angina, Myocardial Infarction
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention [PCI]…
- Conditions
- Unstable Angina, Myocardial Infarction, Acute Disease
- Trial name
- NCT00093158
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 13,800 people
- Sponsor
- The Medicines Company
Acute Anterior Myocardial Infarction
Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention
Rapid MI-ICE-Pilot is designed to demonstrate the safety and efficacy of the Celsius Control™ System (CCS) endovascular catheter to reduce the infarct size resulting from acute anterior myocardial infarction when used in…
- Trial name
- NCT00417638
- Testing
- Endovascular cooling by the Celsius Control System, Standard of care
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- ZOLL Circulation, Inc., USA
Cardiac Arrest, Renal Failure
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
To evaluate the effect of automated recording on frequency of recorded scores, number of automated notifications and serious events.
- Conditions
- Cardiac Arrest, Renal Failure, Respiration Failure, Myocardial Infarction
- Trial name
- NCT02973243
- Testing
- Automatic RR Measurement
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- Philips Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.